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Diagnosis of 
Rickettsioses from 
Eschar Swab 
Samples, Algeria
To the Editor: Tick-borne 
rickettsioses are zoonoses caused by 
intracellular bacteria belonging to 
the spotted fever group rickettsiae 
(1). The main clinical signs are high 
fever, maculopapular rash, and an 
inoculation eschar at the site of the 
tick bite (corresponding to the portal 
of entry of rickettsiae into the host). 
Recently, several rickettsioses were 
diagnosed by using swab samples 
from skin lesions (2,3). In an animal 
model, as long as eschars were present, 
rickettsial DNA was detected (2). Our 
aim was to evaluate the advantage of 
skin swab samples for diagnosis of 
rickettsial diseases in a country where 
rickettsioses are endemic (4).
From July 2009 through October 
2010, a total of 39 patients in the 
infectious disease department of Oran 
Teaching Hospital, Algeria (27 men, 
12 women; median age 46.5 years) 
were included in a prospective study. 
The mean (± SD) interval between 
onset of lesions and consultation 
was 7 ± 1.8 days. Underlying 
conditions were present in 13 (33%) 
patients: diabetes (4 patients, 10.2%), 
hypertension (2 patients, 5%), chronic 
renal failure (1 patient, 2.5%), cervical 
cancer (1 patient, 2.5%), bronchial 
cancer (1 patient, 2.5%), and tobacco 
consumption (6 patients, 15%). Fever 
and generalized maculopapular rash 
(also on palms and soles) were found 
for 38 (97.4%) patients, including 
5 (12.8%) with purpuric rash. One 
(2.5%) patient had 2 eschars on 
the back. Eschars were frontal (1 
[2.5%] patient), cervical (3  [7%]), 
axillary (4 [10.2%]), on the back (6 
[15%]), on the abdomen (2 [5%)], 
on the thorax (1 [2.5%]), inguinal (6 
[15%]), on the leg (8 [20.5%]), on 
the arm (1 [2.5%]), on the buttock (2 
[5%]), on the breast (1 [2.5%]), on 
the nipple (1 [2.5%]), on the penis 
(1 [2.5%]), and on the scrotum (2 
[5%]). Conjunctivitis was reported for 
24 (61.5%) patients and myalgia for 
34 (87.8%). Lymphadenopathy was 
found near the eschar for 8 (20.5%) 
patients. Antimicrobial drug therapy 
(doxycycline 200 mg 1×/d) for 3.5 ± 
1.4 days was empirically prescribed 
for all case-patients before diagnoses 
were conﬁ  rmed.
A dry sterile swab (Copan, 
Brescia, Italy) sample was collected 
from the inoculation eschar of each 
patient by the same person (N.M.). 
Two patients had 2 swab samples 
collected from the same eschar. Only 
1 swab sample was collected from 
the patient with 2 eschars. Scabs 
were removed from eschars before 
swabbing. The swabs, while being 
rotated vigorously, were directed to 
the base of the eschar at a 50°–60° 
angle for 5–6 times. For 4 patients, an 
eschar biopsy sample was collected 
under sterile conditions. Swabs were 
then placed back in their tubes and 
stored at –20°C before transportation 
to Unité des Rickettsies, Marseille, 
France.
In the laboratory, each sample 
was placed in 2 mL of culture 
medium. DNA was extracted from 
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200  μL of solution of eschar swab 
or skin biopsy samples by using the 
QIAamp DNA Mini Kit (QIAGEN, 
Hilden, Germany) according to the 
manufacturer’s instructions, with 
a  ﬁ   nal elution volume of 100 μL. 
We used quantitative real-time PCR 
(qPCR) to determine quality of DNA 
extraction and level of housekeeping 
gene coding for β-actin (5) and to 
detect rickettsiae (2,5). Mean (± SD) 
cycle threshold (Ct) value of the β-actin 
gene for all swab samples was 24.9 
(± 2.7). Of 41 swab samples, 26 were 
positive for rickettsial DNA (63.4%) 
by qPCR targeting the RC0338 
gene (5); mean Ct value was 33.99 
(± 2.15). Speciﬁ  c  Rickettsia conorii 
conorii qPCR, targeting the putative 
acetyltransferase gene (2), had 
positive results for 25 (64%) patients; 
Ct values ranged from 31.02 to 38.63. 
This sensitivity is comparable to that 
of PCRs for detecting R. conorii, 
the agent of Mediterranean spotted 
fever, on skin biopsy samples (4,6). 
Mean Ct value for β-actin gene 
ampliﬁ  cation  of  R. conorii conorii–
positive swab samples was 23.84 
(± 2.19), signiﬁ   cantly lower than 
that for R. conorii conorii–negative 
samples (26.84 ± 2.72; p = 0.0003). 
Of 4 patients for whom swab and skin 
biopsy samples were available, 3 had 
positive results.
Opinions of health care providers 
and patients were evaluated by using 
standard questionnaires (Table). 
Most health professionals preferred 
collecting swab samples over biopsy 
samples for patients and for themselves 
(46 vs. 5 and 57 vs. 2, respectively; 
p = 0.0001). Patients from France 
and Algeria also preferred having 
a swab sample taken over a skin 
biopsy sample (43 vs. 7; p = 0.0001). 
Statistical analyses were conducted 
by using GraphPadPrism version 2.0 
(www.graphpad.com/prism/Prism.
htm) to p<0.5.
Swabbing an eschar is a rapid 
and simple technique that can be 
easily performed without risk for the 
side effects associated with biopsy 
sampling. Insufﬁ  cient material taken 
during swabbing, evidenced by high 
Ct values of β-actin, results in low 
rickettsial load, explaining the false-
negative results. This test can be used 
at the bedside or in an outpatient clinic 
and could be useful for epidemiologic 
and clinical studies. Because qPCR 
results can be obtained <4 hours after 
sampling, this technique might be 
useful for point-of-care diagnosis.
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Table. Acceptability of swab or biopsy samples from tick-bite eschars, Oran Teaching Hospital, Oran, Algeria, July 2009–October 2010
Question
Answer, no. (%)* 
Eschar swab 
sample
Skin biopsy 
sample
Both
samples Nothing
For medical or biologist practitioners, n = 78 
  In the case that your patient has a “tache noire,” what would you do to confirm
   the diagnosis? 
46 (59)  5 (6.4)  22 (28)  5 (6.4) 
  If you have a “tache noire,” what do you do to confirm the diagnosis?  57 (73)  2 (2.5)  9 (11.5)  9 (11.5) 
For patients, n = 58 
  In the case of inoculation eschar, which kind of medical procedure would you  
  prefer your medical doctor to conduct? 
43 (74)  78 (12)  5 (8.6)  3 (5.2) 
*p = 0.0001 for eschar swab sample vs. skin biopsy sample; p value not available for other parameters. 
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